STING Ligand Loaded Nano DDS for Cancer Immunotherapy

Original lipid nano particles(LNPs) with INF stimulator(Cyclic-di-GMP) showed dramatic activity as a cancer adjuvant.

Core Benefit

  • Efficient cytosolic delivery and improved encapsulating / endosomal escape efficiency of Cyclic-di-GMP(c-di-GMP) by the structural feature
  • Drastically enhanced antitumor effect by combination with anti-PD-1mAb

Background and Technology

Stimulator of interferon genes (STING) pathway agonists are now being extensively developed as a new class of cancer therapeutics. STING is an adaptor protein that plays an important role in the activation of type I interferons in response to cytosolic nucleic acid ligands. Recent evidence indicates involvement of the STING pathway in the induction of antitumor immune response. c-di-GMP is a STING ligand and was derived from natural substances and as the chemical synthesizing process was completed we were able to acquire c-di-GMP on a gram scale. However, the delivery efficiency to transmembrane was low.

The inventor group has constructed an original series of LNPs, named YSK05, YSK12-C4, YSK13 which have two fatty acid chains and unsaturated carbon chains. These LNPs loaded c-di-GMP effectively improved transmembrane, activated NK cells and induced antitumor effects against malignant melanomas and represent a possibility as a new adjuvant system for use in cancer immunotherapy.

8-3-2018

Patent status

WO2015/178343 (EP;15796352.1; US;15/311644,JP;2016-521092) and new patent application(not published yet)

Inventors

Hideyoshi Harashima,Yusuke Sato  / Faculty of Pharmaceutical Sciences, Hokkaido University

Expectations

We are looking for a partner to develop or use appropriate LNPs from our library for drug delivery. We can share more data with you under CDA and provide you with samples of our LNPs under MTA.

Product No:CD-02757

 

Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name

Message

Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.

<Notice>

Our support is provided free of charge.
The information submitted on this form is for business development use only.

About Bionauts.jp Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.